AR095660A1 - Métodos de fabricación para el control el contenido de lisina c-terminal, galactosa y ácido siálico en proteínas recombinantes - Google Patents
Métodos de fabricación para el control el contenido de lisina c-terminal, galactosa y ácido siálico en proteínas recombinantesInfo
- Publication number
- AR095660A1 AR095660A1 ARP140100976A ARP140100976A AR095660A1 AR 095660 A1 AR095660 A1 AR 095660A1 AR P140100976 A ARP140100976 A AR P140100976A AR P140100976 A ARP140100976 A AR P140100976A AR 095660 A1 AR095660 A1 AR 095660A1
- Authority
- AR
- Argentina
- Prior art keywords
- content
- terminal
- synalic
- lisin
- galactose
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
Abstract
En la presente descripción se proporciona un método para producir un anticuerpo, como un anticuerpo inhibidor del Factor de Necrosis Tumoral a (anti-TNFa), por ejemplo, infliximab, que tiene un contenido de lisina C-terminal de aproximadamente 20% a aproximadamente 70%, y un contenido de ácido siálico de aproximadamente 1% a aproximadamente 20%, que comprende el cultivo de una célula que responde al zinc transfectada con ADN que codifica el anticuerpo en el medio de cultivo que comprende al menos 0,5 mM de zinc; y controlar la concentración de zinc en el medio de cultivo, y produce, de este modo, el anticuerpo.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361791094P | 2013-03-15 | 2013-03-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR095660A1 true AR095660A1 (es) | 2015-11-04 |
Family
ID=51528780
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP140100976A AR095660A1 (es) | 2013-03-15 | 2014-03-13 | Métodos de fabricación para el control el contenido de lisina c-terminal, galactosa y ácido siálico en proteínas recombinantes |
ARP220100291A AR124871A2 (es) | 2013-03-15 | 2022-02-14 | Métodos de fabricación para el control del contenido de lisina c-terminal, galactosa y ácido siálico en proteínas recombinantes |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP220100291A AR124871A2 (es) | 2013-03-15 | 2022-02-14 | Métodos de fabricación para el control del contenido de lisina c-terminal, galactosa y ácido siálico en proteínas recombinantes |
Country Status (26)
Country | Link |
---|---|
US (3) | US20140273092A1 (es) |
EP (1) | EP2970980B2 (es) |
JP (1) | JP2016512029A (es) |
KR (1) | KR102216003B1 (es) |
CN (1) | CN105378086B (es) |
AR (2) | AR095660A1 (es) |
AU (2) | AU2014237635B2 (es) |
BR (1) | BR112015022971B1 (es) |
CA (1) | CA2907140A1 (es) |
CY (1) | CY1120980T1 (es) |
DK (1) | DK2970980T3 (es) |
EA (1) | EA201591807A1 (es) |
ES (1) | ES2690047T3 (es) |
HR (1) | HRP20181741T1 (es) |
IL (1) | IL240689B (es) |
LT (1) | LT2970980T (es) |
MX (1) | MX366910B (es) |
PH (1) | PH12015501837B1 (es) |
PL (1) | PL2970980T3 (es) |
PT (1) | PT2970980T (es) |
RS (1) | RS57791B1 (es) |
SG (1) | SG11201507577RA (es) |
SI (1) | SI2970980T1 (es) |
TW (1) | TWI630216B (es) |
WO (1) | WO2014149935A1 (es) |
ZA (1) | ZA201507671B (es) |
Families Citing this family (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012149197A2 (en) | 2011-04-27 | 2012-11-01 | Abbott Laboratories | Methods for controlling the galactosylation profile of recombinantly-expressed proteins |
US9067990B2 (en) | 2013-03-14 | 2015-06-30 | Abbvie, Inc. | Protein purification using displacement chromatography |
US9150645B2 (en) | 2012-04-20 | 2015-10-06 | Abbvie, Inc. | Cell culture methods to reduce acidic species |
US9181572B2 (en) | 2012-04-20 | 2015-11-10 | Abbvie, Inc. | Methods to modulate lysine variant distribution |
US9512214B2 (en) | 2012-09-02 | 2016-12-06 | Abbvie, Inc. | Methods to control protein heterogeneity |
WO2014143205A1 (en) | 2013-03-12 | 2014-09-18 | Abbvie Inc. | Human antibodies that bind human tnf-alpha and methods of preparing the same |
US9017687B1 (en) | 2013-10-18 | 2015-04-28 | Abbvie, Inc. | Low acidic species compositions and methods for producing and using the same using displacement chromatography |
WO2014151878A2 (en) | 2013-03-14 | 2014-09-25 | Abbvie Inc. | Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides |
WO2014149935A1 (en) * | 2013-03-15 | 2014-09-25 | Janssen Biotech, Inc. | Manufacturing methods to control c-terminal lysine, galactose and sialic acid content in recombinant proteins |
JP2016527911A (ja) | 2013-08-20 | 2016-09-15 | レック・ファーマシューティカルズ・ディー・ディーLek Pharmaceuticals D.D. | ポリペプチドのα−アミド化および/またはC末端アミノ酸開裂を制御するための細胞培養用培地およびプロセス |
EP3052640A2 (en) | 2013-10-04 | 2016-08-10 | AbbVie Inc. | Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins |
US9181337B2 (en) | 2013-10-18 | 2015-11-10 | Abbvie, Inc. | Modulated lysine variant species compositions and methods for producing and using the same |
US9085618B2 (en) | 2013-10-18 | 2015-07-21 | Abbvie, Inc. | Low acidic species compositions and methods for producing and using the same |
WO2015073884A2 (en) | 2013-11-15 | 2015-05-21 | Abbvie, Inc. | Glycoengineered binding protein compositions |
AU2016348391A1 (en) | 2015-11-03 | 2018-05-17 | Janssen Biotech, Inc. | Antibodies specifically binding TIM-3 and their uses |
WO2017083224A1 (en) * | 2015-11-09 | 2017-05-18 | Bristol-Myers Squibb Company | Methods to manipulate quality attributes of polypeptides produced in cho cells |
US20180355043A1 (en) | 2015-12-17 | 2018-12-13 | Janssen Biotech, Inc. | Antibodies Specifically Binding HLA-DR and Their Uses |
CN109863170A (zh) | 2016-08-12 | 2019-06-07 | 詹森生物科技公司 | 具有增强的激动作用和效应子功能的工程化抗体及其他含Fc结构域分子 |
CA3033665A1 (en) | 2016-08-12 | 2018-02-15 | Janssen Biotech, Inc. | Fc engineered anti-tnfr superfamily member antibodies having enhanced agonistic activity and methods of using them |
EP3634486A4 (en) | 2017-06-05 | 2021-03-31 | Janssen Biotech, Inc. | GENETICALLY PRODUCED MULTISPECIFIC ANTIBODIES AND OTHER MULTIMERIC PROTEINS WITH ASYMMETRIC MUTATIONS OF THE CH2-CH3 REGION |
AU2018282094A1 (en) | 2017-06-05 | 2019-12-12 | Janssen Biotech, Inc. | Antibodies that specifically bind PD-1 and methods of use |
WO2019077628A1 (en) * | 2017-10-16 | 2019-04-25 | Council Of Scientific & Industrial Research | ZINC SUPPLEMENTATION TO DECREASE GALACTOSYLATION OF RECOMBINANT GLYCOPROTEINS |
EP3802607A2 (en) | 2018-05-24 | 2021-04-14 | Janssen Biotech, Inc. | Monospecific and multispecific anti-tmeff2 antibodies and there uses |
AU2019419372A1 (en) * | 2018-12-31 | 2021-07-08 | Momenta Pharmaceuticals, Inc. | Methods of producing ustekinumab |
TW202118788A (zh) | 2019-07-26 | 2021-05-16 | 美商健生生物科技公司 | 包含血管舒緩素相關肽酶2抗原結合域之蛋白質及其用途 |
PE20220299A1 (es) | 2019-08-15 | 2022-03-07 | Janssen Biotech Inc | Materiales y metodos para fragmentos variables de cadena unica mejorados |
KR20220154728A (ko) | 2020-03-13 | 2022-11-22 | 얀센 바이오테크 인코포레이티드 | Siglec-3/cd33을 결합시키기 위한 물질 및 방법 |
KR20230017841A (ko) | 2020-05-27 | 2023-02-06 | 얀센 바이오테크 인코포레이티드 | Cd3 항원 결합 도메인을 포함하는 단백질 및 이의 용도 |
AR123083A1 (es) | 2020-07-29 | 2022-10-26 | Janssen Biotech Inc | Proteínas que comprenden dominios de unión al antígeno hla-g y sus usos |
JP2023544890A (ja) | 2020-10-13 | 2023-10-25 | ヤンセン バイオテツク,インコーポレーテツド | 分化抗原群iv及び/又はviiiを調節するための生物工学的に作製されたt細胞媒介免疫、材料及び他の方法 |
EP4232479A1 (en) | 2020-10-22 | 2023-08-30 | Janssen Biotech, Inc. | Proteins comprising delta-like ligand 3 (dll3) antigen binding domains and their uses |
WO2022162518A2 (en) | 2021-01-28 | 2022-08-04 | Janssen Biotech, Inc. | Psma binding proteins and uses thereof |
IL306103A (en) | 2021-03-24 | 2023-11-01 | Janssen Biotech Inc | The antibody targets CD22 and CD79B |
BR112023019458A2 (pt) | 2021-03-24 | 2023-12-05 | Janssen Biotech Inc | Proteínas que compreendem domínios de ligação ao antígeno de cd3 e usos dos mesmos |
TW202328193A (zh) | 2021-09-13 | 2023-07-16 | 美商健生生物科技公司 | 用於治療癌症的CD33 x Vδ2多特異性抗體 |
WO2023046322A1 (en) | 2021-09-24 | 2023-03-30 | Janssen Pharmaceutica Nv | Proteins comprising cd20 binding domains, and uses thereof |
WO2023089587A1 (en) | 2021-11-22 | 2023-05-25 | Janssen Biotech, Inc. | Compositions comprising enhanced multispecific binding agents for an immune response |
WO2024089551A1 (en) | 2022-10-25 | 2024-05-02 | Janssen Biotech, Inc. | Msln and cd3 binding agents and methods of use thereof |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4376110A (en) | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
US4870163A (en) | 1985-08-29 | 1989-09-26 | New York Blood Center, Inc. | Preparation of pure human tumor necrosis factor and hybridomas producing monoclonal antibodies to human tumor necrosis factor |
DE3631229A1 (de) | 1986-09-13 | 1988-03-24 | Basf Ag | Monoklonale antikoerper gegen humanen tumornekrosefaktor (tnf) und deren verwendung |
EP0288088B1 (en) | 1987-04-24 | 1994-03-09 | Teijin Limited | Detection of tumor necrosis factor; monoclonal antibody and kit |
DK0486526T3 (da) | 1989-08-07 | 1996-06-24 | Peptide Technology Ltd | Bindingsligander for tumornekrosefaktor |
US6277969B1 (en) * | 1991-03-18 | 2001-08-21 | New York University | Anti-TNF antibodies and peptides of human tumor necrosis factor |
US5919452A (en) | 1991-03-18 | 1999-07-06 | New York University | Methods of treating TNFα-mediated disease using chimeric anti-TNF antibodies |
DE07012626T1 (de) | 1991-03-18 | 2010-01-21 | New York University | Monoklonale und chimäre Antikörper gegen humanen Tumornekrosefaktor |
US7192584B2 (en) | 1991-03-18 | 2007-03-20 | Centocor, Inc. | Methods of treating psoriasis with anti-TNF antibodies |
FR2807767B1 (fr) | 2000-04-12 | 2005-01-14 | Lab Francais Du Fractionnement | Anticorps monoclonaux anti-d |
UA81743C2 (uk) | 2000-08-07 | 2008-02-11 | Центокор, Инк. | МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ |
CA2450289A1 (en) | 2003-03-20 | 2005-05-19 | Imclone Systems Incorporated | Method of producing an antibody to epidermal growth factor receptor |
US20040185047A1 (en) | 2003-03-21 | 2004-09-23 | Jill Giles-Komar | Anti- TNF antibodies, compositions, methods and uses |
WO2006108455A1 (en) | 2004-11-02 | 2006-10-19 | Ares Trading S.A. | Serum-free cell culture medium for mammalian cells |
JP5628790B2 (ja) * | 2008-04-07 | 2014-11-19 | バイエル・ヘルスケア・エルエルシー | 糖タンパク質の組換え生産の方法 |
ES2560470T3 (es) * | 2011-04-29 | 2016-02-19 | Biocon Research Limited | Un método para reducir la heterogeneidad de anticuerpos y un proceso de producción de dichos anticuerpos |
WO2013009648A2 (en) | 2011-07-08 | 2013-01-17 | Momenta Pharmaceuticals, Inc. | Cell culture process |
US9181572B2 (en) * | 2012-04-20 | 2015-11-10 | Abbvie, Inc. | Methods to modulate lysine variant distribution |
WO2014149935A1 (en) * | 2013-03-15 | 2014-09-25 | Janssen Biotech, Inc. | Manufacturing methods to control c-terminal lysine, galactose and sialic acid content in recombinant proteins |
-
2014
- 2014-03-07 WO PCT/US2014/021574 patent/WO2014149935A1/en active Application Filing
- 2014-03-07 EP EP14768761.0A patent/EP2970980B2/en active Active
- 2014-03-07 SG SG11201507577RA patent/SG11201507577RA/en unknown
- 2014-03-07 ES ES14768761.0T patent/ES2690047T3/es active Active
- 2014-03-07 PT PT14768761T patent/PT2970980T/pt unknown
- 2014-03-07 SI SI201430848T patent/SI2970980T1/sl unknown
- 2014-03-07 EA EA201591807A patent/EA201591807A1/ru unknown
- 2014-03-07 MX MX2015012361A patent/MX366910B/es active IP Right Grant
- 2014-03-07 LT LTEP14768761.0T patent/LT2970980T/lt unknown
- 2014-03-07 AU AU2014237635A patent/AU2014237635B2/en not_active Ceased
- 2014-03-07 JP JP2016500790A patent/JP2016512029A/ja active Pending
- 2014-03-07 DK DK14768761.0T patent/DK2970980T3/en active
- 2014-03-07 CA CA2907140A patent/CA2907140A1/en active Pending
- 2014-03-07 RS RS20181228A patent/RS57791B1/sr unknown
- 2014-03-07 CN CN201480015815.5A patent/CN105378086B/zh not_active Expired - Fee Related
- 2014-03-07 KR KR1020157029490A patent/KR102216003B1/ko active IP Right Grant
- 2014-03-07 BR BR112015022971-9A patent/BR112015022971B1/pt not_active IP Right Cessation
- 2014-03-07 PL PL14768761T patent/PL2970980T3/pl unknown
- 2014-03-13 US US14/207,915 patent/US20140273092A1/en not_active Abandoned
- 2014-03-13 AR ARP140100976A patent/AR095660A1/es not_active Application Discontinuation
- 2014-03-13 TW TW103108900A patent/TWI630216B/zh not_active IP Right Cessation
-
2015
- 2015-08-20 PH PH12015501837A patent/PH12015501837B1/en unknown
- 2015-08-20 IL IL240689A patent/IL240689B/en unknown
- 2015-10-14 ZA ZA2015/07671A patent/ZA201507671B/en unknown
- 2015-12-23 US US14/757,691 patent/US11149085B2/en active Active
-
2018
- 2018-10-23 HR HRP20181741TT patent/HRP20181741T1/hr unknown
- 2018-11-02 CY CY181101150T patent/CY1120980T1/el unknown
-
2020
- 2020-06-11 AU AU2020203864A patent/AU2020203864B2/en not_active Ceased
-
2021
- 2021-09-29 US US17/489,744 patent/US20220089712A1/en not_active Abandoned
-
2022
- 2022-02-14 AR ARP220100291A patent/AR124871A2/es unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR124871A2 (es) | Métodos de fabricación para el control del contenido de lisina c-terminal, galactosa y ácido siálico en proteínas recombinantes | |
PH12017501114A1 (en) | Anti-c5 antibodies and methods of use | |
MX2018002121A (es) | Elaboracion de fosfatasas alcalinas. | |
PH12018501282A1 (en) | Anti-c5 antibodies and methods of use | |
MX2016004564A (es) | Cultivo celular metabolicamente optimizado. | |
MX2015014608A (es) | Novedosas moleculas de union biespecifica con actividad antitumoral. | |
SG10201901417UA (en) | Production of proteins in glutamine-free cell culture media | |
CL2011000792A1 (es) | Acido nucleico aislado que codifica mutante del factor de crecimiento de fibroblastos 21 (fgf21); vector; celula huesped; fgf21 mutante; proceso de produccion; composicion farmaceutica que lo comprende; y metodo para tratar un trastorno metabolico. | |
MX2019003427A (es) | Composiciones para cultivo celular y metodos para la produccion de polipeptidos. | |
AR095418A1 (es) | Métodos para aumentar el contenido de manosa en proteínas recombinantes | |
AR089324A1 (es) | Composiciones, metodos y kits para la preparacion de proteinas recombinantes sialiladas | |
MX368656B (es) | Métodos mejorados para la producción de polipéptidos recombinantes. | |
NZ705575A (en) | Recombinant clostridium botulinum neurotoxins | |
MX2015008875A (es) | Metodos para la purificacion de arilsulfatasa a. | |
IN2014CN03077A (es) | ||
EA201590550A1 (ru) | Композиции и способы получения гликопротеинов | |
EA202190736A1 (ru) | Способы и композиции для увеличения экспрессии белка и/или лечения расстройства, связанного с гаплонедостаточностью | |
MX2016011465A (es) | Drimenol-sintasas y metodos para producir drimenol. | |
MY180183A (en) | Methods and compositions for preventing norleucine misincorporation into proteins | |
MY182443A (en) | Method of producing lipid | |
MX2013012986A (es) | Plantas que tienen uno o mas rasgos mejorados relacionados con el rendimento y un metodo para producirlas. | |
MX2015010887A (es) | Formulaciones y metodos para aumentar la produccion de proteinas recombinantes. | |
MX2013013063A (es) | Plantas que tienen rasgos mejorados relacionados con el rendimiento y metodo para elaborar las mismas. | |
MX2019005315A (es) | Produccion de particulas similares a picornavirus en plantas. | |
AR094716A1 (es) | Utilización de una cepa procariótica de auxotrofía para aminoácidos revertida para la producción recombinante de un polipéptido |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Refusal |